Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma after radical hepatectomy: a real world study.
Conclusion: Currently, we concluded that not all of patients with HCC would benefit from adjuvant TACE. Patients with age ≥50 years, tumor size >5 cm, or CN stage Ib/IIa were strongly recommended to receive adjuvant TACE.
PMID: 31686555 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cirrhosis | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | PET Scan | Study | Urology & Nephrology